Thomas Steyer Farallon Capital Management
Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
COL
Rockwell Collins
COL
|
+$391M |
| 2 |
MON
Monsanto Co
MON
|
+$386M |
| 3 |
Keurig Dr Pepper
KDP
|
+$362M |
| 4 |
LOGM
LogMein, Inc.
LOGM
|
+$212M |
| 5 |
TFCF
Twenty-First Century Fox, Inc. Class B
TFCF
|
+$182M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
TWX
Time Warner Inc
TWX
|
+$306M |
| 2 |
AABA
Altaba Inc
AABA
|
+$248M |
| 3 |
AB InBev
BUD
|
+$164M |
| 4 |
CPN
Calpine Corporation
CPN
|
+$163M |
| 5 |
Huntsman Corp
HUN
|
+$80.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.51% |
| 2 | Healthcare | 15.68% |
| 3 | Communication Services | 13.68% |
| 4 | Financials | 11.37% |
| 5 | Industrials | 10.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AHL
76
DELISTED
ASPEN Insurance Holding Limited
AHL
| $8.72M | 0.06% |
+194,341
| New | +$7.62M |
|
77
Protagonist Therapeutics
PTGX
$9.99B
| $8.71M | 0.06% |
1,013,500
+113,500
| +13% | +$2.14M |
|
|
GRFS
78
Grifois
GRFS
$5.44B
| $8.33M | 0.06% |
392,804
-1,015,956
| -72% | -$23.1M |
|
|
MRTX
79
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $8.29M | 0.06% |
+270,000
| New | +$7.49M |
|
|
CBAY
80
DELISTED
Cymabay Therapeutics
CBAY
| $7.14M | 0.05% |
550,000
-550,000
| -50% | -$6.83M |
|
81
VICI Properties
VICI
$29.2B
| $6.07M | 0.04% |
+337,049
| New | +$6.59M |
|
82
Xencor
XNCR
$2.07B
| $4.49M | 0.03% |
+149,900
| New | +$3.92M |
|
|
CBIO
83
Crescent Biopharma
CBIO
$637M
| $4.06M | 0.03% |
+2,500
| New | +$5.2M |
|
|
TYME
84
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $3.19M | 0.02% |
+1,430,289
| New | +$5.83M |
|
|
GCVRZ
85
DELISTED
Sanofi Contingent Value Rights
GCVRZ
| $2.88M | 0.02% |
6,827,805
| – | – |
|
86
Arcus Biosciences
RCUS
$3.86B
| $176K | ﹤0.01% |
+11,422
| New | +$190K |
|
87
AbbVie
ABBV
$468B
| – | – |
-700,000
| Closed | -$67.7M |
|
88
Akebia Therapeutics
AKBA
$251M
| – | – |
-825,000
| Closed | -$12.3M |
|
89
AnaptysBio
ANAB
$1.71B
| – | – |
-561,000
| Closed | -$56.5M |
|
90
Assembly Biosciences
ASMB
$700M
| – | – |
-20,833
| Closed | -$11.3M |
|
91
Brookdale Senior Living
BKD
$2.82B
| – | – |
-330,000
| Closed | -$3.2M |
|
92
Bristol-Myers Squibb
BMY
$137B
| – | – |
-1,192,500
| Closed | -$73.1M |
|
|
93
AB InBev
BUD
$155B
| – | – |
-1,470,192
| Closed | -$164M |
|
94
Editas Medicine
EDIT
$478M
| – | – |
-515,000
| Closed | -$15.8M |
|
|
95
Huntsman Corp
HUN
$1.75B
| – | – |
-2,425,000
| Closed | -$80.7M |
|
96
Ionis Pharmaceuticals
IONS
$9.93B
| – | – |
-645,000
| Closed | -$32.4M |
|
97
KALA BIO
KALA
$15.9M
| – | – |
-74
| Closed | -$3.42M |
|
98
PUT
Lumen
LUMN
$6.13B
| – | – |
-1,144,000
| Closed | -$19.1M |
|
|
NCNA
99
NuCana
NCNA
$6.33M
| – | – |
-80
| Closed | -$4.04M |
|
100
Spectrum Brands
SPB
$2B
| – | – |
-170,000
| Closed | -$19.1M |
|
Similar funds
Thomas Steyer's Q1 2018 Portfolio in Review
As of Q1 2018, Thomas Steyer held 108 positions worth $14.4B, up 17% from $12.3B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Thomas Steyer deployed $2.21B of net new capital in Q1 2018, opening 27 new positions and adding to 43 existing holdings. Its largest new stake was Keurig Dr Pepper: 3,265,800 shares worth $387M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Communication Services.
On the sell side, the largest reduction was Time Warner Inc, an estimated $306M trimmed.
- Thomas Steyer's largest Q1 2018 buy was Keurig Dr Pepper: 3,265,800 shares worth $387M.
- Thomas Steyer added most to Rockwell Collins in Q1 2018, an estimated $391M increase.
- Thomas Steyer's biggest Q1 2018 reduction was Time Warner Inc, cutting an estimated $306M.
- Thomas Steyer fully exited AB InBev in Q1 2018, selling an estimated $164M.
- Thomas Steyer's ten largest holdings make up 54% of its $14.4B portfolio in Q1 2018.
- Thomas Steyer opened 27 new positions and closed 22 in Q1 2018.
- Thomas Steyer's portfolio value rose 17% quarter-over-quarter to $14.4B.
Based on Farallon Capital Management's 13F filing for Q1 2018, filed 15 May 2018.